Cost-utility analysis of treatments for stage IB cervical cancer.
- Author:
Kanyarat KATANYOO
1
;
Naiyana PRADITSITTHIKORN
;
Siriwan TANGJITGAMOL
;
Sumonmal MANUSIRIVITHAYA
;
Busaba SUPAWATTANABODEE
Author Information
- Publication Type:Meta-Analysis ; Original Article
- Keywords: Cervical cancer; Concurrent chemoradiotherapy; Cost-utility analysis; Radical hysterectomy; Stage IB
- MeSH: Asian Continental Ancestry Group; Chemoradiotherapy; Cost-Benefit Analysis; Decision Trees; Female; Health Expenditures; Humans; Hysterectomy; Life Expectancy; Lymph Node Excision; Medical Records; Quality-Adjusted Life Years; Recurrence; Thailand; Uterine Cervical Neoplasms*
- From:Journal of Gynecologic Oncology 2014;25(2):97-104
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: To analyze the cost-utility of two common clinical practices for stage IB cervical cancer patients from provider and societal viewpoints. METHODS: A decision tree model was conducted to examine value for expenditure between the following: (1) radical hysterectomy with pelvic lymph node dissection (RHPLND) with or without postoperative adjuvant therapy according to the risk of recurrence and (2) concurrent chemoradiotherapy (CCRT). The relevant studies were identified to extract the probability data, and meta-analysis was performed. Direct medical costs were estimated from hospital database and medical records review. Direct non-medical costs and utility parameters were obtained through interviews with patients to estimate quality-adjusted life years (QALYs) outcome. The time horizon was according to the life expectancy of Thai women. RESULTS: From provider viewpoint, RHPLND and CCRT resulted in approximate costs of US $5,281 and US $5,218, respectively. The corresponding costs from societal viewpoint were US $6,533 and US $6,335, respectively. QALYs were 16.40 years for RHPLND and 15.94 years for CCRT. The estimated incremental cost effectiveness ratio of RHPLND in comparison to CCRT from provider and societal viewpoints were US $100/QALY and US $430/QALY, respectively. RHPLND had more cost-effectiveness than CCRT if patients did not need adjuvant therapy. The most effective parameter in model was a direct medical cost of CCRT. At the current ceiling ratio in Thailand, RHPLND provides better value for money than CCRT, with a probability of 75%. CONCLUSION: RHPLND is an efficient treatment for stage IB cervical cancer. This advantage is only for patients who require no adjuvant treatment.
